High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Nutraceutical Combination in Patients With Low-grade Systemic Inflammation

Conditions:   Atherosclerosis;   Inflammation;   Hypercholesterolemia
Interventions:   Dietary Supplement: Nutraceutical Combination;   Other: Standard of Care;   Other: Placebo
Sponsor:   University Of Perugia
Completed - verified April 2015

Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553/REGN727;   Drug: placebo
Sponsor:   Sanofi
Recruiting - verified April 2015

A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

Condition:   Hypercholesterolemia
Interventions:   Drug: Evacetrapib;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Active, not recruiting - verified April 2015

Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Condition:   Hypercholesterolemia
Intervention:   Biological: Evolocumab
Sponsor:   Amgen
Enrolling by invitation - verified April 2015

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: Bococizumab (PF-04950615; RN316);   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2015

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: Bococizumab (PF-04950615;RN316);   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2015

Open Label Study of Long Term Safety Evaluation of Alirocumab

Condition:   Hypercholesterolemia
Intervention:   Drug: Alirocumab SAR236553 (REGN727)
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Enrolling by invitation - verified April 2015

Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia

Conditions:   Low CETP Activity;   CETP Deficiency;   Hyperalphalipoproteinemia;   Hyper-LDL-cholesterolemia;   High Level of Remnant Cholesterol
Intervention:  
Sponsors:   Osaka University;   Merck Sharp & Dohme Corp.
Recruiting - verified August 2013

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Recruiting - verified April 2015

Genetic Influence on Statin Pharmacokinetics

Conditions:   Hyperlipidemia;   Hypercholesterolemia;   Dyslipidemia
Intervention:  
Sponsors:   Ohio State University;   National Institute of General Medical Sciences (NIGMS)
Recruiting - verified April 2015

Genetic Influence on Statin Pharmacodynamics

Conditions:   Hyperlipidemia;   Hypercholesterolemia;   Dyslipidemia
Intervention:  
Sponsors:   Ohio State University;   National Institute of General Medical Sciences (NIGMS)
Recruiting - verified April 2015

Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

Conditions:   Hyperlipoproteinemia Type II;   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: Anacetrapib;   Drug: Placebo for Anacetrapib
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2015

A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia

Condition:   Hyperlipidemia
Interventions:   Dietary Supplement: Vitamin D3;   Other: Placebo
Sponsor:   Avera McKennan Hospital & University Health Center
Withdrawn - verified April 2015

Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

Conditions:   Hypercholesterolemia;   Dyslipidemia
Interventions:   Biological: Placebo;   Biological: 1 mg/kg every 2 weeks;   Biological: 2 mg/kg every 4 weeks;   Biological: 4 mg/kg every 4 weeks;   Biological: 4 mg/kg every 8 weeks;   Biological: 8 mg/kg every 8 weeks;   Biological: 12 mg/kg every 8 weeks
Sponsor:   Pfizer
Withdrawn - verified April 2015

Impact of Statins on Cytokine Expression in Pneumonia

Conditions:   Community Acquired Pneumonia;   Cardiovascular Risk Factors
Interventions:   Drug: simvastatin;   Drug: Placebo
Sponsor:   The University of Texas Health Science Center at San Antonio
Withdrawn - verified April 2015

Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack

Conditions:   Ischemic Stroke;   Transient Ischemic Attacks
Interventions:   Drug: Antihypertensive agents and lipid lowering therapy;   Other: Usual Care
Sponsors:   University of Alberta;   Heart and Stroke Foundation of Canada;   Alberta Heritage Foundation for Medical Research
Completed - verified April 2015

Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)

Conditions:   Hypercholesterolemia;   Atherosclerosis
Interventions:   Drug: Ezetimibe + Atorvastatin;   Drug: Atorvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)

Conditions:   Hypercholesterolaemia;   Atherosclerosis
Interventions:   Drug: Ezetimibe + Simvastatin;   Drug: Simvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)

Conditions:   Hypercholesterolemia;   Atherosclerosis
Interventions:   Drug: Ezetimibe + Simvastatin;   Drug: Simvastatin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified April 2015

Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)

Conditions:   Atherosclerosis;   Hypercholesterolemia;   Coronary Heart Disease
Interventions:   Drug: Ezetimibe;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)

Conditions:   Hypercholesterolemia;   Atherosclerosis
Interventions:   Drug: Ezetimibe;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Merck Frosst Canada Ltd.
Terminated - verified April 2015

Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)

Conditions:   Hypercholesterolemia;   Atherosclerosis
Interventions:   Drug: Ezetimibe + Rosuvastatin;   Drug: Rosuvastatin;   Drug: Placebo;   Drug: Ezetimibe
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)

Conditions:   Atherosclerosis;   Hypercholesterolemia;   Hyperlipoproteinemia Type II
Interventions:   Drug: ezetimibe (plus simvastatin);   Drug: placebo (plus simvastatin)
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels

Conditions:   Hypertension;   Hyperlipidemia
Intervention:   Drug: Amlodipine/atorvastatin single pill
Sponsor:   Pfizer
Completed - verified April 2015

Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.

Conditions:   Hypercholesterolemia, Familial;   Hyperlipidemia
Interventions:   Drug: torcetrapib/atorvastatin;   Drug: atorvastatin
Sponsor:   Pfizer
Completed - verified April 2015

Get CardioSmart

You're Invited